CEO Christopher Boerner warned at the J.P. Morgan Healthcare Conference in January 2024, two months into his tenure as chief exec of Bristol Myers Squibb, that the company would navigate a few years of losses of exclusivity for key products between 2025 and 2030, with a return to revenue growth later in the decade. That scenario played out on 6 February when BMS reported good 2024 revenue growth, but its 2025 guidance suggests a nearly $3bn year-over-year decline.
Bristol’s 2025 Guidance Falls Short, But CEO Boerner Warned This Was Coming
$2bn In Cost Cuts Planned; Medicare Redesign Neutral
Boerner warned a year ago that BMS may see its revenue falter in the middle of this decade and the company’s 2025 guidance suggests that will happen this year after 2024 beat consensus.
More from Earnings
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.